In a woman with ovarian cancer diagnosed one year ago, how frequently should PET‑CT be used for routine surveillance?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 11, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

PET-CT Surveillance Frequency for Ovarian Cancer

PET-CT should NOT be used for routine surveillance in ovarian cancer patients at any time interval, including one year post-diagnosis. 1

Evidence-Based Surveillance Approach

The Society of Gynecologic Oncologists explicitly states there is insufficient data to support routine use of PET-CT (or any radiographic imaging) for ovarian cancer surveillance at all time points: 0-12 months, 12-24 months, 24-36 months, 3-5 years, and beyond 5 years. 1

Recommended Surveillance Schedule at 1 Year Post-Diagnosis

At 12 months post-diagnosis, patients fall into the 12-24 month surveillance window where the following is recommended: 1

  • Clinical examination every 3 months including comprehensive symptom review, speculum examination, bimanual pelvic examination, and rectovaginal examination 1
  • CA-125 monitoring is optional (should be discussed with patient regarding pros and cons) 1
  • No routine imaging of any kind including PET-CT, CT, MRI, chest x-ray, or ultrasound 1

When PET-CT IS Indicated

PET-CT should only be obtained when recurrence is suspected based on: 1

  • Rising CA-125 levels 1
  • New or progressive symptoms 1
  • Abnormal physical examination findings 1

Diagnostic Algorithm for Suspected Recurrence

When recurrence is suspected, the recommended imaging approach is: 1

  1. First-line: CT chest/abdomen/pelvis with IV contrast to determine disease extent 1
  2. Second-line: PET-CT is used as an adjunct when CT findings are indeterminate or equivocal 1

Performance Characteristics of PET-CT

While PET-CT demonstrates variable sensitivity (45-100%) and specificity (40-100%) with overall diagnostic accuracy of 95%, this does not justify routine surveillance use. 1 Research shows PET-CT is particularly valuable for detecting recurrence when CA-125 is rising but conventional CT/MRI is negative or inconclusive. 2, 3, 4

Critical Rationale Against Routine Surveillance Imaging

The guidelines explicitly recommend against routine imaging because: 1

  • No mortality benefit: Early detection of asymptomatic recurrence has not been proven to improve survival outcomes 1
  • Limited treatment options: Recurrent ovarian cancer remains largely incurable with second-line therapies offering only short-term progression-free survival 1
  • Cost and radiation exposure: Routine PET-CT surveillance exposes patients to unnecessary radiation and healthcare costs without proven benefit 1

Important Nuance from Research

A 2009 meta-analysis found PET-CT had the highest pooled sensitivity (0.91) for detecting recurrent disease, with an AUC of 0.9555, superior to CT alone (AUC 0.8845). 3 However, this diagnostic accuracy in symptomatic or high-suspicion patients does not translate to benefit in asymptomatic routine surveillance, which is why guidelines maintain their position against routine use. 1

Common Pitfalls to Avoid

  • Do not order "routine" or "surveillance" PET-CT scans at any predetermined interval 1
  • Do not substitute PET-CT for clinical examination - physical exam remains the cornerstone of surveillance 1
  • Do not obtain PET-CT based solely on patient anxiety without objective clinical indicators of recurrence 1
  • Do not skip the CT scan and go directly to PET-CT when recurrence is suspected - CT should be obtained first 1

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Surveillance procedures for patients treated for epithelial ovarian cancer: a review of the literature.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2007

Research

PET-CT in recurrent ovarian cancer: initial observations.

Radiographics : a review publication of the Radiological Society of North America, Inc, 2004

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.